Xencor, Inc.
COMPLEMENT COMPONENT C5 ANTIBODIES

Last updated:

Abstract:

The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.

Status:
Application
Type:

Utility

Filling date:

24 Aug 2020

Issue date:

8 Apr 2021